<DOC>
	<DOCNO>NCT00232258</DOCNO>
	<brief_summary>To evaluate safety efficacy clinical symptom , mucosal histology endoscopic mucosal appearance two dos SR140333B placebo patient mild moderate ulcerative colitis resistant treatment 5-ASA .</brief_summary>
	<brief_title>Nolpitantium Besylate In Patients With Ulcerative Colitis Double-Blind , Placebo Controlled Efficacy Safety Study</brief_title>
	<detailed_description>Patients active mild moderate ulcerative colitis respond minimum 4 week 5-ASA randomized receive single daily dos either placebo , 600 mg SR140333B 1800 mg SR140333B eight week . Patients undergo baseline end study sigmoidoscopic assessment complete daily symptom diary study . Ulcerative colitis disease activity measure overall component subscores Mayo Disease Activity Index .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Age least 18 year Ulcerative colitis least 6 month duration Patient 's ulcerative colitis remain active take 5ASA sulfasalazine least 4 week If taking corticosteroid , dose must stable least 2 week prior enrollment exceed 20 mg per day ( prednisolone equivalent ) Crohn 's disease Colonic dysplasia Stool culture positive enteric pathogen Concurrent cancer unstable medical condition Recent treatment monoclonal antibody Recent introduction thiazolidinedione Recent treatment methotrexate cyclosporine Recent treatment antibiotic prescribe ulcerative colitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>NK1 Antagonist</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
	<keyword>Mesalamine</keyword>
</DOC>